SK Biopharm Applies for FDA Approval of Cenobamate Oral Suspension
Expansion of Indications to Pediatric Patients Targeting Adults With Partial-Onset Seizures
Broader Clinical Use Expected Following Pharmacokinetic Equivalence Confirmation
On April 1, SK Biopharm announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for the oral suspension formulation of cenobamate (marketed in the U.S. as Xcopri), a treatment for epilepsy.
This application seeks to add a liquid formulation in addition to the existing tablet, targeting adult patients with partial-onset seizures. The aim is to improve dosing convenience, especially for patients who have difficulty swallowing tablets, as the oral suspension can be administered to them as well.
The oral suspension formulation allows for easy dose adjustment depending on the patient's condition or treatment environment.
Cenobamate is currently also undergoing clinical trials in pediatric patients. SK Biopharm intends to gradually expand the indicated age range based on the results of these pediatric clinical trials and the current application for adults.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
Lee Donghoon, CEO of SK Biopharm, stated, "The oral suspension formulation of cenobamate is the result of reflecting the treatment needs of patients who have difficulty taking tablets."
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.